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Abstract 
 
Background 
Patients with schizophrenia have substantially reduced ‘Subjective Wellbeing’ (SW) 
compared to healthy individuals. It has been suggested that diminished SW may be related to 
deficits in the neural processing of reward but this has not directly been shown. It was 
hypothesized that in schizophrenia lower SW will be associated with attenuated reward-
related activation in the ‘reward network’. 
 
 
Methods  
Twenty patients with schizophrenia with a range of SW underwent an fMRI reward task. The 
brain activity underlying reward ‘anticipation’ and ‘outcome’ in schizophrenia was examined 
and compared to those of 12 healthy participants using a full factorial analysis. Region of 
interest of areas within the reward network and whole-brain analyses were conducted to 
reveal neural correlates of SW. 
 
 
Results 
Reward-related neural activity in schizophrenia was not significantly different to healthy 
participants, however, the patients with schizophrenia showed significantly diminished SW. 
Both ROI and whole-brain analyses confirmed that SW scores in the patients correlated 
significantly with activity specifically in the dorsal anterior cingulate cortex (dACC) during 
both reward anticipation and reward outcome. This association was not seen in the healthy 
participants.  
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Conclusions 
In patients with schizophrenia reduced activation of the dACC during multiple aspects of 
reward processing is associated with lower Subjective Wellbeing. As the dACC has been 
widely linked to coupling of reward and action, and the link to SW is apparent over 
anticipation and outcome, these findings suggest that SW deficits in schizophrenia may be 
attributable to reduced integration of environmental rewarding cues, motivated behaviour and 
reward outcome. 
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Introduction 
 While treatment of schizophrenia has focussed on reduction of the clinical presence of 
positive symptoms, there has been increasing recognition of the importance of patients’ 
subjective experiences of illness as an important therapeutic target and key predictor of 
outcome (Karow et al., 2007). Approximately one third of patients with schizophrenia treated 
with antipsychotic medication experience dysphoria (Voruganti et al., 2001) which can 
influence clinical and functional outcome and compliance (Naber et al., 2005). Patient 
Subjective Wellbeing (SW) can be measured with the Subjective Wellbeing under 
Neuroleptics scale (SWN (Naber, 1995)) which assesses patients’ psychological and 
emotional state and can be differentiated from other related constructs such as depression and 
anhedonia. SW is a multidimensional construct and measures patients’ perceptions of social 
integration, self-control, emotional-regulation, mental functioning, and physical functioning. 
It is also a distinct outcome measure in schizophrenia (Lambert & Naber, 2004) and is a 
central predictor of medication compliance (Karow et al., 2007); however, the neural basis of 
poor SW remains unclear.  
Subjective experience is intricately linked with dopaminergic functioning and reward 
processing. Alterations in dopaminergic tone manifest negative changes to subjective 
experience, such as increased dysphoria, and lower subjective well-being following 
consumption of antipsychotic administration (Voruganti & Awad, 2004), the administration of 
which depletes dopaminergic transmission (de Haan et al., 2000). Accordingly SW is 
generally higher in patients treated with atypical rather than typical antipsychotics despite 
similar efficacy in reducing positive symptoms (Naber et al., 2001; Karow & Naber, 2002) 
most likely due to these compounds producing lower striatal D2 receptor blockade. The level 
of ventral striatal (VS) dopamine receptor binding is associated with SW in medicated 
patients with schizophrenia (Mizrahi et al., 2007). The ventral striatum is central to reward 
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processing, and it has been widely shown that activation in the VS is elevated during reward 
anticipation (e.g. Schott et al., 2008). The VS signal reflects DA activity (Knuston & Gibbs, 
2007), and this signal has been shown to be absent in healthy participants following 
dopamine-depletion with AMPT (da Silva Alves et al., 2010).  
Together this evidence then suggests that the relationship between SW and altered 
dopaminergic function may be underpinned by a central role of dopamine in reward-based 
learning. In this way, the antipsychotic olanzapine (a dopamine antagonist) which reduces 
reward-related brain activation in the reward network (Abler et al., 2007), interferes with 
neural activation in reward areas during reward processing and reduces subjective experience 
in healthy participants after only a single dose (Schlagenhauf et al., 2007). Reduced 
anticipation of reward in schizophrenia is also associated with anhedonia (Gard et al., 2007). 
Dysfunction of the reward network in patients with schizophrenia will, therefore, negatively 
impact processing of, and motivation towards, environmental reward cues, which we propose 
forms the mechanism for low SW in schizophrenia.  
SW has, however, been shown to improve with the antipsychotic aripiprazole despite 
high striatal D2 receptor blockade (Mizrahi et al, 2009) and Mizrahi et al. (2007) report 
strong correlations between SW and D2 receptor binding in cortical brain regions. These 
findings suggest SW is not just a function of striatal D2 receptor binding and may be related 
to functioning of extra-striatal brain regions. In following, this study aimed to investigate the 
neural correlates of SW in schizophrenia using fMRI, specifically the relationship between 
SW and activation of the 'reward network' in response to rewarding stimuli but also across the 
whole-brain to investigate extra-striatal neural correlates. We primarily hypothesized that in 
schizophrenia patients lower SW will be associated with attenuated reward-related activation 
in regions of the ‘reward network’ and this would be confirmed by ROI analyses of these 
regions. Also, SW-related changes in activation in these regions will be greater in the 
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anticipatory phase than the outcome phase. It has recently been suggested that the SWN 
scale, despite being designed for use in schizophrenia, may be valid in healthy volunteers 
(Vothknecht et al., 2012) hence we carried out a subsequent exploratory analysis 
investigating whether there was a similar relationship between SW and brain activity in 
healthy participants. 
 
Method 
Design 
 Patients with schizophrenia and healthy control participants underwent fMRI during a 
modified Monetary Incentive Delay reward task (see Knutson et al., 2001). Behavioural data 
were analysed to establish the degree to which performance and ratings of outcome were 
related to SW. The fMRI data were analysed to examine (a) brain activation during the 
anticipatory and consummatory phases of the reward task per se in patients and healthy 
participants; and (b) brain activity within areas of the reward network which correlated with 
SW scores using region of interest analyses. Whole-brain analyses were also conducted to 
reveal areas of the brain other than reward-regions which correlated with SW. 
 
Participants 
 Twenty male dextral patients with DSM-IV diagnosis of schizophrenia and twelve 
healthy participants took part. Patients were on average 36.5 years old (sd=6.9) and had an 
average National Adult Reading Test-2 (Nelson & Willison, 1991) IQ score of 101.6 
(sd=11.6). Healthy participants had a mean age of 30.7 years (sd=7.3) and an IQ of 106.4 
(sd=9.2), thus patients were on average 5 years older, but neither IQ scores nor ages were 
significantly different. 
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 Patients were moderately symptomatic (Positive And Negative Syndrome Scale (Kay 
et al., 1987) mean total  = 57.5 (sd=15.2) (subscale means (sd): positive scale = 15.8 (7.3), 
negative scale = 13.7 (5.6) and general scale = 28.1 (6.3)) and had low extrapyramidal side 
effects (Simpson-Angus Scale (Simpson & Angus, 1970) mean=4.54 (sd=3.2), 
Extrapyramidal Symptom Rating Scale (Chouinard et al., 1980) mean = 2.14 (sd=2.6) and 
Barnes Akathisia scale (Barnes, 1989) mean=1.33 (sd=3.2; median = 0.0)). None of the 20 
patients had Parkinsonism. 
Six patients received olanzapine (7.5-25mg), 4 risperidone (2-6mg; one patient: 
37.5mg/14days of risperidone consta), 2 zuclopenthixol (400mg), 2 clozapine (50-300mg), 1 
flupentixol (30mg/14days), two quetiapine (100/300mg), one received aripiprazole (20mg). , 
one received combination chlorpromazine (100mg) and sulpride (600mg) and one was 
unmedicated (Chlorpromazine equivalent dose mean = 229.5, sd=145.72, range 75-600). 
After complete description of the study to the subjects, written informed consent was 
obtained. Ethical approval was provided by Camden and Islington Community Local 
Research Ethics Committee (ref: 08/H0722/22). 
 
Measures 
 All participants completed the following scales: Subjective Well-being under 
Neuroleptics scale short version (20 items, 7-pt Likert scale; (Naber, 1995)) which provides a 
SW score out of 120 points and quantifies judgements on five factors: emotional regulation, 
mental functioning, physical functioning, self-control, and social integration; and the Beck 
Depression Inventory-2 (Beck et al., 1996). The SWN is best interpreted as a total score 
(Vothknecht et al., 2012) as used here. The patients also completed the Simpson-Angus Scale, 
Extrapyramidal Symptom Rating Scale, and the Barnes Akathisia scale measures of 
medication side-effects.  
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fMRI procedure 
 Subjects completed a version of the Monetary Incentive Delay (MID) task (Knutson 
et al., 2001) in which visual cues predict potential outcome, and where performance – the 
reaction time of a button press to a target - determines reward outcome. The two phases 
examined in the study are the anticipatory phase (after the cue presentation); and an outcome 
phase (trial outcome).  All participants were trained before the scanning session to preclude 
measuring learning mechanisms. Each 18.5s trial consisted of cue presentation (duration 2-8 
seconds), followed by presentation of a brief ‘target’ square (initially 250ms, then adjusted by 
the algorithm) then, after a delay of 2-8 seconds the outcome of the trial is displayed for 2-8 
seconds.  
There were five cue types: large win, small win, small loss, large loss and neutral (no 
financial reward or punishment). Each of three fMRI runs (see Figure 1) consisted of 24 trials 
each of high reward (HR; £5) low reward (LR; £0.5), small loss (SL -£0.5) and large loss 
(LL; -£5) trials and 48 control trials (where there was no potential for gain or loss), giving a 
total of 144 trials. Hitting the target that appears after the cue (button press RT within the 
target window) results in a positive outcome: financial gain in the ‘win’ trials, and prevention 
of loss in the ‘lose’ trials. Missing the target (reacting too slowly) results in negative 
outcome:  no gain in the ‘win’ trials, and a loss in the ‘lose’ trials. An algorithm shifts the 
target reaction time window such that the participant 'hits' in 66% of trials, and 'misses' in 
34% of trials ensuring sufficient data for 'hit' and 'miss' trials irrespective of relative absolute 
performance. Each of three runs lasted 14m 48s producing a total scan time of 44m24s. 
 Participants then rate their satisfaction at the outcome on a 9-point Likert visual 
analogue scale (VAS) from “not satisfied” to “very satisfied” (duration 3 seconds). This was 
included so as to be sure that patients exhibited a range of subjective valences that reflected 
reward outcome differences to demonstrate that the task elicited subjectively rewarding 
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responses. There was a final 0.5 second ‘fixation cross’. All money won and lost by the 
participant was representational, however, to ensure motivation, and anticipation and 
outcome effects, payment to participants was proportional to their game profits (between £15 
and £25). 
 
Scanning parameters 
 448 gradient-echo echo-planar BOLD images (TR/TE: 2000/25 ms, flip angle: 75°, 
matrix: 64 x 64, FOV=220) were acquired on a 3 Tesla GE Excite II MR scanner (GE 
Healthcare, USA) during each of run of the task. Each whole-brain image contained 38 non-
contiguous slices of 2.4-mm thickness separated by a distance of 1 mm and an in-plane 
isotropic voxel resolution of 3.4 mm. 
 
Analysis 
Behavioural data analysis 
 Mean consummatory VAS scores of post-outcome satisfaction for each cue type and 
target response (hit and miss) were calculated. A repeated-measures ANOVA was conducted 
to reveal effects of valence (positive or negative outcome), magnitude of outcome, target 
response, and group on VAS scores. Between-groups ANOVA of total money accrued by 
participants were conducted. Further correlation analyses were conducted to determine the 
relationship between VAS scores and SW and to examine the relationship between CPZ-
equivalent dose and outcomes scores in the patients. 
 
fMRI data processing and analysis 
 fMRI data were preprocessed and analysed using SPM5 (Statistical Parametric 
Mapping, Wellcome Department of Imaging Neuroscience, University of London, UK). Data 
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were realigned across sessions to the first image of the first image of the first series, 
normalised to a standard-brain template and smoothed using an 8-mm FWHM Gaussian 
kernel. Analyses were conducted in the context of the general linear model (Friston et al., 
1998) to determine: 
(i) brain regions associated with reward processing (anticipation and outcome) to 
reveal any abnormalities in reward-processing in the patient group in the first 
instance; and; 
(ii) whether ROI analyses of the reward network would reveal that SW in the 
patient group was associated with reward-related BOLD response in the 
reward network and whether whole-brain analyses would reveal whether 
activity in other, non-reward network areas correlated with SW; and, 
(iii) whether the healthy participants showed a similar pattern. 
  
Reward related activations 
 First-level event-related general linear models (GLMs) were constructed for each 
participant. GLMs included a regressor predicting the BOLD response to each of 2 phases 
(anticipation/outcome), 5 cue types (high reward/ low reward/control trials/low loss/high 
loss) by outcomes (win/lose) convolving a vector of delta functions for the onset of the 
stimuli for that condition with the canonical haemodynamic response function. Effects of 
head motion were minimised by the inclusion of six realignment parameter vectors as 
regressors of no interest. These first level contrast images were entered into a second-level, 
random-effects 2 x 5 x 2 full-factorial analysis. The main effects of anticipation and outcome 
were then established (p<.05, FWE-corrected) for the two groups to confirm that the task 
elicits reward-related activity; and group x reward interaction effects were investigated at 
p<.05 FWE-corrected to reveal any group differences. MNI co-ordinates were converted to 
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Talairach space using mni2tal (Brett; http://imaging.mrc-
cbu.cam.ac.uk/imaging/MniTalairach). 
 
SW analysis 
 For the patient group the principal covariate of interest, total SW score, was included 
in a full-factorial model to identify brain regions where activity correlated with SW scores.  
Regions of interest (ROI) were chosen of 4 key a priori regions based on previous 
publications: anterior cingulate cortex (ACC), cingulate gyrus (CG), ventral striatum (VS), 
and caudate nuclei (CN) regions (see Haber & Knuston, 2010). The ventral striatum mask 
was taken from Mawlawi et al. (2001), the remainder from Pickatlas software (Maldjian et 
al., 2003). As multiple ROIs were being investigated the significance level (α) for assessing 
effects from the ROI analysis was Bonferroni corrected to p<.0125 (FWE-corrected). 
Separate and combined analyses were conducted for the anticipation and outcome phases. A 
final whole brain analysis was also performed to examine areas outside the reward network 
which correlated with SW. The significance threshold for whole-brain analyses was set at 
p<.05 (FWE-corrected). These analyses were also conducted in an exploratory fashion in the 
healthy participants. 
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Results 
 
Subjective Well-being 
 Patients (mean = 87.1 (sd = 14.1) showed significantly lower SW than healthy 
volunteers (mean = 100.5 (sd = 13.6), p<0.01). Figure 1 below shows the distribution of SW 
scores for the two groups. The patients showed mild levels of depression (mean BDI score = 
11.8 (sd=9.2) which was significantly greater than the healthy controls (mean = 4.4 (sd=4.3) 
(p <0.01). SW and BDI scores significantly correlated (r=-0.7, p<.005) 
 
---- Figure 1 here ---- 
Behavioural data 
 As expected, hit outcomes rated on the VAS scale, were judged more satisfying than 
miss outcomes (F(1,31)=109.4, p<.001); rewarding trials more satisfying that loss trials 
(F(1,31)=39.30, p<.001) and larger rewards more satisfying than smaller rewards 
(F(1,31)=8.55, p<.01). There were no group effects of hit rates or reaction times (see table 1). 
There was also no main effect of group on VAS scores, nor with respect to outcome or 
magnitude of reward. There was a modest difference on VAS scores between the groups with 
respect to trial valence (F(1,31)=5.51, p<.05). Patients were less dissatisfied at missing an 
opportunity to avoid a loss than were controls (see figure 2): this was evident as a trend for 
small losses and as a statistically significant effect for large losses (t(1,31)=2.65, p<.05). 
Healthy participants (mean = 57.29 (sd=18.83) gained significantly more money than the 
patients (mean = 28.87 (sd=38.70) (t(1,31)=2.37, p=.024). CPZ-equivalent dose did not 
correlate with VAS or hit rate performance measures but did correlate with mean reaction 
reaction time (r=0.48, p=.032). 
 
---- Figure 2 here ---- 
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SW and VAS scores in the patient group 
 There were no significant correlations between average absolute hit or miss VAS 
scores, nor VAS scores subtracting control trial VAS scores, with subjective well-being scores 
in any condition. Neither the mean nor condition-specific reaction times correlated with SW 
(all p>0.05). 
 
fMRI  
Reward anticipation  
Reward anticipation for all participants was associated with activity in several clusters 
covering bilateral inferior frontal and superior temporal gyri, insula and ventral striatum, as 
well as medial frontal and cingulate gyri, left pre- and post-central gyri, thalamic medial 
dorsal nuclei, right parahippocampal gyrus, and left and right brainstem (Figure 3A, p<.05 
FWE-corrected; Figure 3B shows separate overlaid groups maps). There were no voxels 
showing a significant group x reward interaction, even with a liberal threshold (p<.001 
uncorrected) indicating no significant between-groups differences in brain region activation 
involved in reward anticipation.  
 
---- Figure 3 here ---- 
Reward outcome 
 There was a significant main effect (p<.05 FWE-corrected) of reward at outcome in 
the right inferior parietal lobule, right middle and inferior frontal gyri, bilateral thalamus and 
cerebellum/declive; and a small region within the right superior temporal gyrus. There was no 
group x condition interaction, even with a liberal threshold (p<.001), indicating that the 
patients and healthy participants were not significantly different in terms of the brain regions 
involved in processing reward outcome.   
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Subjective Well-being in schizophrenia 
 Within the patient group a single model incorporating both anticipation and outcome 
phases of the task revealed that SW was related to activation within the anterior cingulate 
cortex (ACC) in both ROI (p<.0125 FWE-corrected) and whole-brain analyses (p<.05, FWE-
corrected; see conjunction image in figure 3C, below). The relationship between brain 
activation and SW across phases was unique to the ACC and not seen in any other brain 
region. This relationship was robust across phases of reward anticipation as shown by 
separate analyses of these phases, below. 
 
Anticipation and Subjective Wellbeing 
 Several cortical areas were significantly associated with SW (FWE, p<.05), including 
anterior cingulate cortex (ROI-level, p<.01 FWE-corrected; whole-brain analysis, all peak 
voxels p<.05 FWE-corrected; see table 2;). In the whole-brain analyses significant 
associations were also apparent within the occipital lobe and bilateral middle frontal gyri. 
 
---- Table 1 here ----  
 
Outcome and Subjective Wellbeing 
 Region of interest analyses revealed a significant associated with ACC activation  
(p<.01, FWE-corrected) but not in cingulate gyrus, caudate or ventral striatum masks. In the 
whole-brain analysis, several regions were significantly associated with SW in the outcome 
phase (p<.05, FWE) including in the ACC and within the posterior cingulate (negatively, 
peak voxel p<.01, FWE-corrected). Since these additional regions activated were not 
hypothesized we list them as a table (see table 2 below) but do not venture a further 
interpretation at this time. Subsequent posthoc analysis showed that the beta coefficients for 
the association of SW with miss outcomes were significantly greater than for hit trials 
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(F(1,9)=5.99, p<.05). In order to discount the possibility that reaction times to stimuli may 
impact on BOLD response in this study, a final analysis was conducted which showed that 
reactions times did not correlate with activity in the ACC region associated with SW scores. 
Also, to show that the reward and SW effects are not confounded by medication a further 
post-hoc analysis demonstrated that neither reward-related activity nor activity in regions 
which showed an association with SW were associated with chlorpromazine-equivalent 
(CPZ) dose (p<.001 uncorrected). There was ample variation in CPZ dose for a relationship 
to be detected had one been present. 
 
---- Table 2 here ----  
 
Mood and reward processing 
 A final post-hoc analysis was conducted to investigate the relationship between mood 
(as measured by the BDI) and reward-related activation in the patient group to investigate the 
specificity of SW to dACC activation. The SW vector was replaced by the BDI vector and the 
analyses were re-run. No regions within the regions of interest correlated significantly with 
BDI during the anticipation phase however during the outcome phase the dACC was 
significantly correlated with neural activation as shown by both R.O.I. and whole-brain 
analyses (p<.05 FWE-corrected; locus at 2,12,26). 
 
Healthy Participants and Subjective Wellbeing 
In healthy participants there were no significant associations with SW seen at the 
whole-brain analysis in, or near the region dACC region, nor in the R.O.I. analyses. Between-
groups analysis confirmed that the relationship between SW and activity in the dACC was 
significantly greater in patients compared to healthy participants (p<.0001). 
16  
 
Discussion 
 This study examined the neural correlates of Subjective Wellbeing (SW) in 
schizophrenia using a monetary incentive delay (MID) reward paradigm in order to test the 
hypothesis that reward network activity is associated with SW. As anticipated, the level of 
SW was significantly lower overall in the patients compared to healthy controls. Reward-
related neural activity in both groups during anticipation of reward was consistent with that 
seen in previous studies and involved the insula, ventral striatal and supplementary 
motor/motor area activity. Both healthy participants and patients demonstrated good 
discrimination of reward outcome as shown by visual analogue scale ratings supporting the 
fact that cues and outcomes were rewarding in nature. 
As expected, ventral striatal (VS) activity represented anticipation to rewarding 
stimuli, consistent with other studies (e.g. Knutson et al., 2001), yet there were no significant 
differences in VS activity (whole-brain or region-of-interest) between the patients and healthy 
volunteers. It has previously been shown that patients treated with the newer atypical 
antipsychotics at appropriate doses show ‘normalised’ VS reward-related activity relative to 
healthy participants (Schlagenhauf  et al., 2007; Abler et al., 2008; Juckel et al., 2006) 
potentially reflecting a putative normalising effect of these medications on dopaminergic 
transmission.  
 We anticipated that activation of the reward network would underpin subjective 
wellbeing scores. In line with this, a dorsal region of the anterior cingulate cortex (dACC) 
was significantly associated with SW scores, however, contrary to expectation this was 
observed in both the anticipation and outcome phases rather than the anticipation period 
alone. The dorsal ACC has been linked to a range of cognitive processes, such as attention, 
cognitive control, conflict-monitoring, response inhibition, self-reflection, and set-switching 
capacity, and is also involved in the modulation of reward processing through its widespread 
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projections to affective, cognitive, and motor cortical areas (see Haber & Knutson, 2010). 
Critchley et al. (2001) reported that a distinct region of anterior cingulate (slightly more 
anterior than the locus reported here) was commonly activated by both uncertainty and 
arousal in a reward task suggesting the dACC represents both expected reward and 
motivation. Considerable evidence shows that the ACC is active during reward anticipation 
(e.g.  Kirsch et al., 2003; Knutson et al., 2008) and single-cell neurons in the dACC in 
humans have been shown to ‘code’ reward properties while dACC ablation disrupts reward-
related behavioural adjustment (Williams et al., 2004). The dACC thus plays a key role in 
forming associations between reward and appropriate action (Haber & Knutston, 2010). As 
activity in this region is associated with SW in both anticipatory and outcome phases it 
suggests that dACC may represent the motivational significance of current actions or 
cognitions (Ochsner et al., 2001) and integrate rewarding environmental cues, behaviour and 
outcome.   
Absent dACC activation has been reported in patients with schizophrenia during 
anticipation of reward (Quintana et al., 2004; Abler et al., 2008), and the effects of 
olanzapine in healthy participants reported by Abler et al. (2007) extend to include dorsal 
anterior cingulate activity (proximally located to the peak voxel that correlated with SW in 
this study) which was one of three regions, including the VS, reduced by olanzapine 
compared to placebo during reward-related processing. Healthy volunteers also show reduced 
anterior cingulate activity after AMPT-related dopamine depletion (de Silva Alves et al., 
2010). Hence, these compounds that act to reduce dopaminergic transmission also reduce 
reward-related dorsal anterior cingulate activity.  
 ACC activity has also been linked with depression (Bench et al., 1992) and more 
rostrally and ventrally with anhedonia in healthy participants (Keedwell et al., 2005; Harvey 
et al., 2007). Patients with Major Depression have been shown to differ from healthy subjects 
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in the relationship between valence of reward anticipation and ACC, but not nucleus 
accumbens activity (Knutson et al., 2008); and those who respond clinically to antidepressant 
medication show increases in ACC D2 receptor binding that is greater than increases in VS 
binding (Larisch et al., 1997). Hence, together there may be a strong link between ACC 
functioning and a broader sense of well-being.   
 The strong relationship between SW and dACC activation was not seen in the 
exploratory analysis in the healthy participants. In healthy individuals, while acute AMPT 
reduces reward-network activation, it had no significant effect on SWN scores (Da Silva 
Alves et al., 2010) despite effects on dACC and striatal activation. Specificity of this 
association to patients may be attributable to the gross differences in dopaminergic reward 
system functioning in schizophrenia relative to healthy people per se, or alternatively or 
additionally via the further impact that antipsychotic medication has on these systems. It may 
also be the case that the scale is more ecologically-valid in patient groups, following 
neuroleptic administration - the sequelae of which the scale has been designed to measure, or, 
with respect to the lack of association between DA changes and SW reported by Da Silva 
Alves et al. (2010), that the scale is not sensitive to drug effects over a short period of time. 
The sample size in the healthy group was also small which may account for lack of positive 
association and the SWN item questions are of a more general nature rather than would relate 
to acute and short-term ‘state’ effects. Further resolution of this discrepancy is beyond the 
scope of this paper, but future research should extend examination of the neural correlates of 
SW in the healthy population and in a larger group. 
 It was proposed that SW must have a dopaminergic foundation to account for the 
relationship between reduced SW and antipsychotic medication. Whilst there is no direct 
evidence linking the two in the present study, there is support for an effect of antipsychotic 
action on ACC function. Antipsychotic medication is associated with reduced ACC rCBF in 
19  
 
patients with schizophrenia (Miller et al., 1997), whilst impaired activation in a similar dorsal 
ACC location in schizophrenia patients can be restored with apomorphine administration 
(Dolan et al., 1995) – a D1/2 agonist - demonstrating that there is a significant 
neuromodulatory effect of dopamine on ACC functioning. While it is not possible in the 
context of this study, without data on receptor occupancy, to conclusively report that low SW 
leads to attenuated engagement of the ACC in reward processing, the data suggests an 
association which warrants further investigation. 
An association between estimated dopamine D2R occupancy (‘fitting’ medication 
dose to dopamine receptor occupancy data) and positive and negative affect in schizophrenia 
has recently been shown using a daily experiential sampling method (Lataster et al., 2010). 
Greater estimates of receptor occupancy were associated with a worsening of feelings of 
positive and negative affect supporting the link between dopamine and subjective experience 
and adds ecological validity to the present and other studies which investigate subjective 
experience using more general, ‘offline’ questionnaires. 
 We did not find the anticipated correlation between SW and VS activation based on 
earlier data linking antipsychotic medication with impairments in VS functioning. This may 
be due to the VS response to reward in the patient group being unimpaired. As patients had 
lower SW scores, but unimpaired VS activity, this implicitly suggests that VS functioning 
does not underpin SW. Elsewhere Mizrahi and colleagues (Mizrahi et al., 2009) report an 
association between VS dopamine D2 receptor blockade and SW but only in patients 
receiving conventional antipsychotics not those receiving aripiprazole. In patients taking 
aripiprazole, there was a wide range of SW scores (including low scores), at the same time as 
homogenously high VS D2 receptor blockade across the group, again suggesting that SW is 
not simply reducible to VS D2 receptor blockade. Using PET, Mizrahi et al. (Mizrahi et al., 
2007) showed that temporal cortex D2 receptor blockade was more strongly associated with 
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SW than striatal blockade again indicating that the link between striatal function and SW is 
not encapsulated. Lastly, studies which find associations between SW and VS activity, for 
example (Mizrahi et al., 2009), generally only investigated striatal (and cerebellar) regions in 
the first instance. Investigations of other extra-striatal regions, such as the ACC, may reveal 
the activity in these regions provide a fuller account of SW. Despite previous links between 
SW and VS and other reward-network regional DA binding, and medication effects, this 
study demonstrates a functional mechanism between SW reward processing per se. 
 
Limitations  
 Whilst the SWN scale shows good inter-rater reliability and face validity, non-specific 
biases in completing self-relevant questionnaires may impact on SW ratings. Monetary 
reward was only representational - participants received a (lower) amount than trials 
indicated which may have impacted on the rewarding saliency of the cues. However, there is 
little to suggest this was the case given that VS activity was linked to reward in the primary 
analysis and varied by magnitude and valence of reward. Although mean ages were not 
significantly different an improvement would have been to better age-match the groups. CPZ-
equivalent dose was associated with mean reaction time but this is most likely attributable to 
sedative effects of antipsychotic medication on speed of reactions. CPZ-equivalent doses 
were not associated with SWN, subjective VAS ratings nor hit rates.  
There was a moderate correlation between SWN and BDI. Subsequent analysis of the 
neural correlates of BDI scores revealed some of the pattern of findings that SW held with 
reward-related neural activity although this was limited to the outcome not anticipation 
phase. Together this suggests that SW and depression may be overlapping constructs and that 
dACC activity may be related to a broader sense of well-being. However, SWN is not just 
reducible to BDI – a substantial proportion (46%) of the variance of SWN remained 
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unexplained by BDI scores, supporting the utility of conducting independent analyses. Indeed 
SW is the central predictor of medication compliance (Karow et al., 2007) and constitutes a 
distinct outcome measure in schizophrenia (Lambert & Naber, 2004) hence investigating SW 
as a specific target of research is warranted. Examination of the items on these scales also  
reveals that they are founded on different constructs. The SWN focusses on social integration, 
self-control, emotional-regulation, mental functioning, and physical functioning which differ 
from the cognitive and affective components measured by the BDI. Additionally, there may 
be a causal relationship between mood and SW and this could be in either direction, hence 
future research should further examine the precise relationship between these measures and 
the potential dissociation between mood and subjective well-being with respect to 
anticipation and consumption of reward.  
Patients acquired significantly less financial gain than healthy participants. There 
were no significant group differences in hit-rate or reaction time to account for this, however 
as a large cue results in a ‘£5’ gain or loss then attaining winning outcomes on only a few 
additional trials could mean a large difference in the final amount won. Between-groups VAS 
ratings were not significantly different although patients were less sensitive than the healthy 
group to suffering large losses. Lower sensitivity to negative feedback requires further 
investigation, however, Schlagenhauf et al. (2009), recently reported that patients but not 
healthy volunteers show significantly attenuated ventral striatal signal in response to 
suffering loss outcomes compared to avoiding loss outcomes whereas there were no group 
differences after gaining or losing positive reward. Patients with schizophrenia may be 
behaviourally and/or neurally less sensitive to negative outcomes and this may reflect 
disturbed error-signal processing (ibid), or speak to impairments in learning from feedback in 
schizophrenia (Averbeck et al., 2011). 
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Conclusions 
 Patients with schizophrenia showed reduced SW. Activation within a dorsal region of 
the ACC held a significant relationship with SW over both anticipation and outcome phases 
of a reward task which was not seen in the healthy. This could be due to greater disturbance 
of the broader dopaminergic reward system in schizophrenia or via medication effects. The 
ACC is involved in the integration of action and reward and one interpretation is that poor 
SW may result from a reduced coupling and integration of reward, action and outcome. 
Intuitively, a state in which there is decreased functional association or learning between 
reward, action and outcome could manifest an attenuation of one’s sense of well-being if 
actions within a personal repertoire are not linked in a routine way to reward. Future research 
should examine the interaction between reward processes, D2 receptor blockade and SW to 
further identify the anatomical and neurochemical pathways underlying subjective wellbeing 
and identify suitable interventional targets. 
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Figures and tables 
Figure 1 showing the distribution of SW scores for the healthy control (N=12) and patient (N=20) groups. 
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Figure 2 showing patient (N=20) and healthy control (N=12) subjective VAS scores for each condition outcome, as rated after 
reward outcome. Blue lines represents miss trials, and the green lines represent hit trials. 
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Figure 3 showing (A) activity related to anticipation of reward in all participants (p<.05 FWE-corrected); (B) the activation maps of 
common regions of activation for the two groups overlaid (threshold of p<.001 for illustration; yellow=healthy; red=schizophrenia); 
and (C) the unique overlap of the SW-related ACC activation during anticipation (blue) and outcome (red) in the schizophrenia 
group. As can be seen there is a clearly defined overlap at talairach co-ordinates: 2,11, 27. 
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Table 1 showing mean (sd) group hit rate and reaction times for each salient cue type and total amount gained. 
 
Measure Cue 
Group 
Schizophrenia Healthy 
Hit Rate (%) Large Win 60.59 (12.01) 66.05 (7.82) 
Small Win 60.88 (12.59) 67.42 (7.70) 
Large Loss 62.67 (14.07) 68.10 (9.21) 
Small Loss 66.08 (10.28) 66.84 (7.85) 
 Control 37.00 (16.33) 44.44 (12.88) 
Reaction Time (ms) Large Win 243.75 (21.19) 232.52 (22.74) 
Small Win 248.32 (28.45) 245.11 (26.32) 
Large Loss 252.31 (19.71) 233.61 (22.03) 
Small Loss 248.53 (30.24) 236.91  (21.69) 
 Control 273.24 (39.22) 256.68 (39.94) 
Amount Gained (‘£’)  28.87 (38.70) 57.29 (18.83) 
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Table 2 showing the peak voxels and p values (p<0.05, FWE-corrected) that held a significant association with the 
SW covariate during anticipation and outcome.  
 
Phase Hemisphere Region Talairach coordinates F 
peak p (FWE-
corr) 
Anticipation 
R Inferior Occipital Gyrus 36 -88 -4 6.25 0.001 
 L Lingual Gyrus -20 -97 -2 6.05 0.001 
 R Anterior Cingulate 6 9 24 5.8 0.003 
 R Precentral Gyrus 42 -5 59 5.79 0.003 
 R Middle Frontal Gyrus 57 8 38 5.52 0.006 
 L Middle Occipital Gyrus -30 -95 0 5.49 0.007 
 L Middle Frontal Gyrus -32 -3 59 5.06 0.024 
Outcome 
L Cuneus/Occipital lobe -10 -82 36 7.197 <0.001 
 R Lingual gyrus 18 -76 -6 7.185 <0.001 
 R Cuneus/Occipital lobe 10 -94 20 6.954 <0.001 
 L/R Posterior Cingulate 4 -56 2  5.618 <0.005 
 L/R Anterior Cingulate 2 12 28 4.97 <0.05 
 
 
 
 
 
 
 
 
 
 
